TCL Archive Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL March 25, 2011
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI FY94 Budget To Fund 860 Grants, Increase Prevention, Construction Money December 3, 1993
